ABSTRACT: The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a critical regulator of cell growth and is frequently hyperactivated in cancer. Therefore, PI3K inhibitors represent a valuable asset in cancer therapy. Herein we have developed a novel anticancer agent, the potent pan-PI3K inhibitor PQR514 (4), which is a follow-up compound for the phase-II clinical compound PQR309 (1). Compound 4 has an improved potency both in vitro and in cellular assays with respect to its predecessor compounds. It shows superiority in the suppression of cancer cell proliferation and demonstrates significant antitumor activity in an OVCAR-3 xenograft model at concentrations approximately eight times lower than PQR309 (1). The favorable pharmacokinetic profile and a minimal brain penetration promote PQR514 (4) as an optimized candidate for the treatment of systemic tumors.
T he phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) signaling pathway plays a key role in many cellular processes, including cell growth, proliferation, and survival. 1, 2 The PI3K family is divided into three classes according to their amino acid sequences, homology, and substrate specificity. 3 Class-I PI3Ks are activated downstream of cell surface receptors, including receptor protein tyrosine kinases (RTKs), G-protein-coupled receptors (GPCRs), and immunoglobulin receptors. Class-IA PI3Ks are obligate heterodimers composed of a catalytic subunit (p110α, p110β, or p110δ) and an associated regulatory subunit (p85α, p85β, p50α, p55α, or p55γ). The class-IB PI3Kγ operates downstream of GPCRs and consists of a catalytic subunit (p110γ) and an adapter subunit (p84 or p101). 4−6 Activated PI3K produces PtdIns(3,4,5)P 3 , a docking site for protein kinase B (PKB/Akt) and 3-phosphoinositide-dependent protein kinase 1 (PDK1). Overactivation of this pathway can occur at multiple levels, finally promoting cancer growth and progression. 7 The loss or inactivation of the tumor suppressor phosphatase and tensin homologue (PTEN), the mutation or amplification of cell surface receptors, as well as the presence of activating hotspot mutations in PIK3CA play a key role in human carcinogenesis. 8 The PI3K/mTOR axis has been associated with resistance to multiple cancer treatments. Therefore, PI3K inhibitors are considered to be a valuable asset in cancer therapy. A considerable effort has been dedicated to the development of drugs targeting PI3K signaling, and many of them are currently being evaluated in clinical trials. 9 Besides monotherapy, PI3K inhibitors are tested as part of combination regimens.
Recently, we have reported on PQR309 (1, bimiralisib), a brain-penetrant pan-PI3K inhibitor, which also moderately targets mTOR kinase. 10−12 Compound 1 contains a 2-amino-4-(trifluoromethyl)pyridine linked to the triazine core ( Figure  1A ) and is currently in phase-II clinical trials for the treatment of lymphoma and solid tumors.
11 First phase-I clinical results have been disclosed. 13 The effect of replacing the trifluoromethyl moiety with a difluoromethyl group has been investigated (compound 2, Figure 1A ), and the ability of the CHF 2 group to act as a lipophilic hydrogen donor in mTOR kinase has been pointed out to explain the improvement in mTOR affinity (K i 1 = 62 nM; 2 = 6.9 nM, Table 1). 14 In addition, we have converted the pyridine ring of 1 into a pyrimidine moiety (3, Figure 1A ). Compound 3 was a potent inhibitor of PI3K but not of mTOR (Table 1) . Herein we have combined the two chemical modifications of 2 and 3 to develop a novel, improved anticancer agent ( Figure 1A) . We propose the 4-(difluoromethyl)pyrimidin-2-amine as an optimized moiety for PI3K binding. Moreover, we report the preclinical characterization of PQR514 (4), a follow-up compound for 1.
PQR514 (4) has been evaluated for in vitro binding (K i for mTOR and PI3Kα (p110α)) and for PI3K/mTOR signaling in A2058 cells (IC 50 for phosphorylated S6 ribosomal protein (pS6, Ser235/236) to detect mTORC1 activity and protein kinase B (PKB/Akt) phosphorylation on Ser473 to detect mTORC2 activity). Compound 4 was two times more potent on mTOR than the parental inhibitor 1, whereas there was an almost eight-fold difference in PI3K inhibition (K i (mTOR) 1 = 62 nM, 4 = 32.7 nM; K i (p110α) 1 = 17 nM, 4 = 2.2 nM, Table 1 ). To explain the higher affinity for PI3K of the 4-(difluoromethyl)pyrimidin-2-amine compared with the CF 3 -substituted pyridine, we analyzed interactions of compound 4 with the ATP-binding site. The X-ray crystal structure of PQR309 (1) in PI3Kγ had been solved at a 2.7 Å resolution, and the key interactions have been identified (see ref 11 ; PDB code 5OQ4). We have substituted 1 with 4 and performed energy minimization. The resulting PI3Kγ-4 complex showed major interactions such as H bonds between the aminopyrimidine and Asp836/964, and between a morpholine oxygen atom and the backbone amide of Val882. The other solvent-exposed morpholine is stabilized by a H bond between its oxygen atom and the side chain of Lys890 (distance = 3.2 Å, Figure 1B ). The CHF 2 -group could interact with (i) Asp836 or (ii) a triazine core nitrogen, as previously suggested. 14 The presence of many hydrophilic amino acids in the binding pocket of the heteroaromatic ring suggested that a pyrimidine might be better accommodated than a pyridine. The nitrogen a PKB phosphorylation on Ser473 and ribosomal S6 phosphorylation on Ser235/236 were analyzed in A2058 cells exposed to the indicated inhibitors and the subsequent detection of phosphoproteins in an in-cell Western assay. Each experiment performed with n = 2.
b Compounds were tested for the in vitro binding to the ATP-binding site of p110α and mTOR using a commercially available time-resolved FRET (TR-FRET) displacement assay (LanthaScreen). Each experiment performed with n = 2. lgIC 50 values and standard errors are reported in Table S1 . Table S1 . (9) was prepared starting from the commercially available 2,4,6-trichlorotriazine. The chlorine of intermediate 9 was displaced by 4-(difluoromethyl)pyrimidin-2-amine using a Suzuki crosscoupling reaction with the boronic acid pinacol ester generated in situ (see Scheme 1A and the Supporting Information for details). For asymmetric compounds 5−8, the substituted morpholine (M n ) was introduced starting from 2,4-dichloro-6-(morpholin-4-yl)-1,3,5-triazine (14) , and subsequent palladium-catalyzed Suzuki coupling gave the final compounds in moderate to good yield (44−62%). All of the synthesized compounds were highly potent PI3K inhibitors (K i (p110α) < 4.5 nM), also showing a good affinity for mTOR kinase (K i (mTOR) < 35 nM). These results confirmed the 4-(difluoromethyl)pyrimidin-2-amine as an optimized binding module compared with the CF 3 −pyridine of compound 1. Compounds 4−8 were more potent both in vitro and in cells than compound 1 (Tables 1 and 2 ). Among the CHF 2 −pyrimidine derivatives, PQR514 (4) had a superior activity in cells (IC 50 for phosphorylated PKB/Akt = 17 nM, IC 50 for phosphorylated S6 = 61 nM) and was chosen for further characterization using the KINOMEScan platform of DiscoverX. DiscoverX KdELECT assays confirmed the excellent affinity for PI3Ks of 4 (K d PI3Kα/β/δ/γ < 7 nM, Table S2 ). Moreover, PQR514 (4) was screened in a KINOMEScan panel for interactions with a wide range of proteins (>400) and lipid kinases to validate its specificity. At a 10 μM concentration, it showed negligible interference with protein kinase activities ( Figure S1 and Table S3 ) and reached excellent selectivity scores of S(35) = 0.041 and S(10) = 0.025, calculated according to ref 15 (Table S4 ). To evaluate offtarget effects, compound 4 was tested in a CEREP BioPrint (P22-p) panel at a concentration of 10 μM. With the exception of human PDE3A (phosphodiesterase 3A), no or very weak interactions were detected (Tables S5 and S6 ). These data qualify PQR514 (4) as a selective pan-PI3K inhibitor.
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In addition, 4 was screened using a fluorescence highthroughput P450 assay to exclude the inhibition of cytochrome P450 (CYP) enzymes. PQR514 (4) showed half-maximal inhibitory concentration (IC 50 ) >100 μM for all of the P450 isoenzymes tested (CYP1A2, CYP2C19, CYP2D6, and CYP3A4), highlighting the safety profile of the molecule.
PQR514 (4) 
Letter a mean half-maximal growth inhibition (GI 50 ) of 0.25 μM (Figure 2A) . A comparison with the structurally related PQR309 11 (1, GI 50 ∼1 μM) and PQR530 (16, GI 50 ∼0.4 μM; see Figure S2 and ref 16 for the chemical structure) pointed out the superiority of PQR514 (4) (GI 50 of 0.24 μM) in the suppression of cancer cell proliferation in a matched 44 cell line panel ( Figure 2B and Table S7) .
A PAMPA (parallel artificial membrane permeability assay) was performed, and PQR514 (4) showed a high passive permeability (81.96 ± 5.40 nm/s). As an additional indicator of bioavailability, the thermodynamic solubility over a range of pH values as well as in fasted and fed state simulated intestinal fluids (FaSSIF and FeSSIF) was measured (Table S8) . A correlation between solubility, estimated intestinal permeability, and projected clinical potency has been outlined, and even for most potent and highly permeable compounds, a thermodynamic solubility of at least 1 μg/mL is favorable. Compound 4 displayed a solubility >1 μg/mL at all pH values tested, with a maximum at pH 1.2 (13.6 μg/mL, Table S8 ), and thus matched criteria for drug-like compounds.
To assess the in vitro metabolic stability of 4, it was exposed to microsomes and hepatocytes of different origins. PQR514 (4) was only minimally metabolized when incubated with rat, mouse, dog and human liver microsomes, as indicated by, respectively, 109, 82.4, 92.7, and 87.2% remaining compound after 30 min of exposure (Table 3 ). The high stability of 4 in microsomal assays was consistent with clearance and half-life measurements in rat, mouse, dog, and human hepatocyte cultures. PQR514 (4) showed a low clearance in all species. The half life of 4 was 5.8 h in human hepatocytes and 3.2−8.7 h in the other species (Table 4) . PQR514 (4) was then profiled in vivo in mice to evaluate the pharmacological parameters and determine the optimal dosing schedule for efficacy studies. A single oral dose of 10 mg/kg was administered to male C57BL/6J mice, and concentrations of 4 in plasma, brain, and thigh muscle were monitored over time. Pharmacokinetic (PK) parameters are summarized in Table 5 . The maximal concentration (C max ) of PQR514 (4) was reached in plasma after 1 h (3282 ng/mL) and in brain and thigh muscle after 30 min (1023 and 1808 ng/g, respectively) ( Figure 3A and Table 5 ). Compound 4 showed limited brain access and showed a ca. 1:0.3 distribution between plasma and brain. The minimal brain permeability of 4 suggests the possible application in the treatment of systemic tumors, 17 avoiding putative neurological side effects. Neuropsychiatric effects such as anxiety and depression had been observed in patients treated with brain penetrant BKM120 (buparlisib), a pan PI3K inhibitor with microtubule-destabilizing activity, 10 but did not become apparent in a PQR309 (1) phase-I study. 13 The administration of compound 4 in male C57BL/6J mice triggered a rapid increase in plasma insulin and glucose levels. The plasma insulin and glucose levels reached a maximal concentration 2 h after dosing ( Figure 3B,C, respectively) . This rise is a reliable marker for the on-target action of PQR514 (4) and has been observed with other PI3K inhibitors, including PQR309 (1). 11, 18 To assess the in vivo antiproliferative effect of compound 4, an OVCAR-3 xenograft model in BALB/c nude mice was used: Each mouse was inoculated subcutaneously with 5 × 10 6 OVCAR-3 tumor cells for tumor development. From day 17 on, the control group received the vehicle once a day (QD), whereas the treated groups received either 6.3 mg/kg of compound 4 p.o. or 50 mg/kg of compound 1 p.o. QD for 28 days. The mean tumor size of the vehicle-treated group reached 1031 mm 3 on day 45 after tumor inoculation. Treatment with 4 led to a significant antitumor activity: The mean tumor size was 397 mm 3 , as compared with 571 mm 3 after treatment with PQR309 (1) at an eight times higher dose than 4 (6.3 vs 50 mg/kg, Figure 4A ). The results of the tumor weight analysis were consistent with the tumor volume analysis: Compared with vehicle-treated mice, compound 4 significantly inhibited tumor growth ( Figure 4B ). PQR514 (4) was well tolerated at 6.3 mg/kg, and no significant body weight loss was observed ( Figure 4C) . In vivo toxicokinetic studies were carried out to assess the toxic potential of compound 4 and to establish the maximum tolerated dose (MTD). A 14-day pilot study with PQR514 (4) was carried out in Wistar rats and beagle dogs, and the toxicokinetic parameters are summarized in Table S9 . In Wistar rats, the no-observed adverse effect level (NOAEL) of compound 4 was considered to be 2.4 mg/kg/day for females and 3.6 mg/kg/day for males. In beagle dogs, the NOAEL of compound 4 was 10 mg/kg/ day. In summary, we have characterized the 4-(difluoromethyl)-pyrimidin-2-amine moiety as an optimized residue for PI3K binding and proposed PQR514 (4) as a novel anticancer agent that can serve as a follow-up compound for PQR309 (1). 10, 11, 13 Compound 4 demonstrated significant antitumor activity in a mice xenograft model at a concentration almost eight times lower than the parental phase-II inhibitor (1) . On the basis of its remarkable PI3K affinity, favorable pharmacological parameters, safety profile, and in vivo antitumor efficacy, PQR514 (4) qualifies as a targeted anticancer drug with a potential application in the treatment of systemic tumors.
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